Corticosteroids in Severe COVID-19(ASAP-C Study)

Overview

Administration of systemic corticosteroids for patients with severe forms of severe acute respiratory syndrome(SARS-Co-2) infection are recommended by several guidelines. In the very beginning of SARS-Co-2 pandemic the early recommendation by professional organization was against routine use of corticosteroids for patients with coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS), despite previous data and clinical practice for patients with refractory or severe form of ARDS.

Full Title of Study: “Administration of Systemic Corticosteroids Among Critically Ill Patients With COVID-19: Electronic Survey (ASAP-C Study)”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: January 30, 2021

Detailed Description

Administration of systemic corticosteroids for patients with severe forms of SARS-Co-2 infection are recommended by several guidelines. In the very beginning of SARS-Co-2 pandemic the early recommendation by professional organization was against routine use of corticosteroids for patients with coronavirus disease 2019 (COVID-19) ARDS, despite previous data and clinical practice for patients with refractory or severe form of ARDS. But at the latest after publication of RECOVERY trial (Randomized Evaluation of Covid-19 Therapy, July 2020) and ensued metaanalysis of World Health Organization (WHO) working group, the routine administration of systemic corticosteroids was revisited. However, there are ongoing critical debate of the evidence regarding the dose, administration, timing and type of corticosteroids and ongoing randomized controlled trial (RCT) are challenging the recommendation of 6 mg of dexamethasone for all patients with severe form of COVID-19. The dynamic of COVID-19 surges, flip-flop of official recommendations within very short period of time and ongoing critical debate could be with possible variations of daily clinical practice regarding using systemic corticosteroids. In an electronic evaluation form that will be send to European Society of Intensive Care (ESICM) Members. The electronic survey will contain 10 question. In the questionnaire the participants will have to describe their routine clinical practice regarding administration of systemic corticosteroids among patients with COVID-19 ARDS.

Interventions

  • Other: questionnaire
    • Members of European Society of Intensive Care will obtain an electronic survey considering their routine clinical practice regarding the administration of systemic corticosteroids among patients with COVID-19 ARDS

Arms, Groups and Cohorts

  • Members of European Society of Intensive Care
    • Members of European Society of Intensive Care will obtain an electronic survey considering their routine clinical practice regarding the administration of systemic corticosteroids among patients with COVID-19 ARDS

Clinical Trial Outcome Measures

Primary Measures

  • Systemic corticosteroids among patients with COVID-19 ARDS practice – questionnaire (electronic survey)
    • Time Frame: 1 month
    • Administration of systemic corticosteroids among patients with COVID-19 ARDS practice in European countries – questionnaire (electronic survey)

Participating in This Clinical Trial

Inclusion Criteria

  • Members of European Society of Intensive Care Exclusion Criteria:

  • not members of European Society of Intensive Care

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 100 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Brno University Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Petr Štourač, MD, assoc.prof.MD,Ph.D – Brno University Hospital
  • Overall Official(s)
    • Jan Malaska, MD., Ph.D, Principal Investigator, University Hospital Brno
  • Overall Contact(s)
    • Jan Malaska, MD., Ph.D, 532232009, jan.malaska@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.